Trinity Biotech Completes Acquisition of Fitzgerald Industries International
Dublin, Ireland. Trinity Biotech plc announced that it has completed the acquisition of Fitzgerald Industries International, Inc.
Trinity Biotech has acquired the business of Fitzgerald for US$16 million consisting of cash of US$8 million and shares in Trinity Biotech of US$8 million. Fitzgerald provides a comprehensive range of immunodiagnostic products to pharmaceutical companies, reference laboratories, diagnostic manufacturers, universities and research facilities worldwide. The Company's growth has been impressive and profitable with sales growing from $3.8 million for the period ending December 31, 2000 to $7.0 million in 2003 which is a compound growth rate of 23% per annum. The acquisition will be earnings positive in 2004.
The range of products provided by Fitzgerald includes monoclonal and polyclonal antibodies, antigens, proteins, enzymes and immunochemicals employed in the areas of cancer, cardiac, fertility and infectious disease diagnosis. As part of the transaction the principals of Fitzgerald will remain and will continue to direct the operations of Fitzgerald as a stand-alone entity within the Trinity Group.
Ronan O'Caoimh, Trinity Biotech CEO, commented "We are delighted to acquire the business of Fitzgerald Industries which is a business we have admired for many years. This acquisition positions us in an exciting area of the life sciences market with significant potential for future growth. The combination of Fitzgerald's excellent products and Trinity's marketing capabilities through its distributor base in eighty countries worldwide will result in continued ongoing growth within Fitzgerald. We are confident that this business line will become a significant part of the Trinity Group in the coming years. The acquisition will also provide Trinity with the benefits or Fitzgerald's sourcing expertise and in the medium term will provide Trinity with the ability to source raw materials at better prices."
Edward Fitzgerald, President Fitzgerald Industries International, commented "The acquisition of Fitzgerald by Trinity will provide the company with access to a wider distribution base. We are very excited at the opportunities this will present to continue the growth profile of our business and to better serve our customers. It is the intention of both parties that Fitzgerald will continue to operate as a stand-alone entity."
Other news from the department business & finance
These products might interest you
Whatman™ folded filter papers by Cytiva
Whatman folded filter papers
Convenient folded formats speed up your sample preparation
Systec H-Series by Systec
Safe, reproducible and validatable sterilization of liquids, solids and waste
Autoclaves with 65-1580 liters usable space, flexibly expandable for various applications
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
William_Saville-Kent
FundaMental Pharma launches with EUR 10 million in Seed financing to advance a First-in-Class neuroprotectant - "These inhibitors have the potential to revolutionize therapies for currently untreatable neurodegenerative diseases"
Category:Swedish_marine_biologists
Self-healing DNA nanostructures
Vifor Fresenius Medical Care Renal Pharma and Relypsa enter into partnership to commercialize Patiromer FOS
LifeCodexx Successfully Completes Clinical Validation of its Noninvasive Prenatal Test Method of Trisomy 21
A. Constantino & C. S.p.A. - Favria, Italy
Genzyme to Reopen Enrollment in Alglucosidase Alfa Temporary Access Program - Agreement reached on U.S. approval pathway for Pompe disease treatment
